BRPI0904955A2 - Depósito implantável de drogas para reduzir, prevenir ou tratar dor em um paciente em necessidade de tal tratamento e métodos para tratar dor aguda e para fazer um depósito de drogas implantável. - Google Patents

Depósito implantável de drogas para reduzir, prevenir ou tratar dor em um paciente em necessidade de tal tratamento e métodos para tratar dor aguda e para fazer um depósito de drogas implantável.

Info

Publication number
BRPI0904955A2
BRPI0904955A2 BRPI0904955-0A BRPI0904955A BRPI0904955A2 BR PI0904955 A2 BRPI0904955 A2 BR PI0904955A2 BR PI0904955 A BRPI0904955 A BR PI0904955A BR PI0904955 A2 BRPI0904955 A2 BR PI0904955A2
Authority
BR
Brazil
Prior art keywords
drug depot
implantable drug
pain
patient
treatment
Prior art date
Application number
BRPI0904955-0A
Other languages
English (en)
Inventor
John Myers Zanella
Vanja Margareta King
Christopher M Hobot
S Mark Cox
William F Mckay
Kathy L Remsen
Original Assignee
Warsaw Orthopedic Inc
Medtronic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warsaw Orthopedic Inc, Medtronic Inc filed Critical Warsaw Orthopedic Inc
Publication of BRPI0904955A2 publication Critical patent/BRPI0904955A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0904955-0A 2008-04-18 2009-04-13 Depósito implantável de drogas para reduzir, prevenir ou tratar dor em um paciente em necessidade de tal tratamento e métodos para tratar dor aguda e para fazer um depósito de drogas implantável. BRPI0904955A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/105,864 US8524267B2 (en) 2008-04-18 2008-04-18 Dexamethasone formulations in a biodegradable material
PCT/US2009/040295 WO2009129155A2 (en) 2008-04-18 2009-04-13 Dexamethasone formulations in a biodegradable material

Publications (1)

Publication Number Publication Date
BRPI0904955A2 true BRPI0904955A2 (pt) 2015-06-30

Family

ID=41199668

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0904955-0A BRPI0904955A2 (pt) 2008-04-18 2009-04-13 Depósito implantável de drogas para reduzir, prevenir ou tratar dor em um paciente em necessidade de tal tratamento e métodos para tratar dor aguda e para fazer um depósito de drogas implantável.

Country Status (7)

Country Link
US (3) US8524267B2 (pt)
EP (1) EP2187866A4 (pt)
JP (1) JP2011518164A (pt)
CN (1) CN101917968A (pt)
AU (1) AU2009236419A1 (pt)
BR (1) BRPI0904955A2 (pt)
WO (1) WO2009129155A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090110637A1 (en) * 2007-10-26 2009-04-30 Warsaw Orthopedic, Inc. LMP and Regulation of Tissue Growth
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US20110027331A1 (en) * 2009-07-29 2011-02-03 Warsaw Orthopedic, Inc. An implantable drug depot having a reversible phase transition material for treatment of pain and/or inflammation
US8916186B2 (en) * 2009-10-23 2014-12-23 DePuy Synthes Products, LLC Methods and devices for correcting spinal deformity with pharmaceutical-eluting pedicle screws
WO2012122436A2 (en) * 2011-03-08 2012-09-13 The Regents Of The University Of California Molecular zipper tweezers and spring devices
RU2703303C2 (ru) * 2013-05-24 2019-10-16 Данмаркс Текниске Университет Состав геля для лучевой терапии под визуальным контролем
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
DE102014005782A1 (de) * 2014-04-23 2015-10-29 Martin-Luther-Universität Halle-Wittenberg lnjizierbare und implantierbare Trägersysteme auf Basis von modifizierten Poly(dikarbonsäure-multiol estern) zur kontrollierten Wirkstofffreisetzung
US20150342964A1 (en) * 2014-05-30 2015-12-03 Warsaw Orthopedic, Inc. Dexamethasone polymer implant for pain
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
CA3002099A1 (en) 2015-12-30 2017-07-06 Dexcom, Inc. Diffusion resistance layer for analyte sensors
WO2018005541A1 (en) * 2016-06-27 2018-01-04 University Of Iowa Research Foundation Magnetically-activated coating for treating biofilms, and associated systems and methods
PL3548091T3 (pl) 2016-11-29 2022-03-28 Oculis SA Otrzymywanie stałych kompleksów cyklodekstryny do dostarczenia czynnego składnika farmaceutycznego do oczu
WO2019071245A1 (en) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. IMPLANTABLE DEPOSITS FOR REGULATED RELEASE OF ANALGESICS TO TREAT POSTHOPERATIVE PAIN ASSOCIATED WITH ORTHOPEDIC SURGERY, AND RELATED DEVICES, SYSTEMS, AND METHODS
CN116650732A (zh) 2018-01-08 2023-08-29 铸造疗法股份有限公司 经由治疗剂的控制递送用于治疗腔内癌症的装置、系统和方法
US12458589B2 (en) 2018-05-12 2025-11-04 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
WO2020047013A1 (en) 2018-08-28 2020-03-05 Foundry Therapeutics, Inc. Polymer implants
WO2020168106A1 (en) 2019-02-13 2020-08-20 Notable Labs, Inc. Combinations of agonists of protein kinase c with steroids or retinoic acids for the treatment of cancer
DK3993807T3 (da) 2019-07-01 2026-01-19 Oculis Operations Sarl Fremgangsmåde til stabilisering af ph-værden i en vandig sammensætning, der indeholder et lægemiddel
US12383246B2 (en) 2020-10-12 2025-08-12 Abbott Cardiovascular Systems, Inc. Vessel closure device with improved safety and tract hemostasis
GB202019594D0 (en) * 2020-12-11 2021-01-27 Univ London Queen Mary Sustained release formulations of crystalline drugs

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
DK0659073T3 (da) * 1992-09-10 2002-03-11 Childrens Medical Center Bionedbrydelige polymermatrixer med vedvarerende afgivelse af lokalanæstetika
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
JP4642946B2 (ja) * 1996-12-20 2011-03-02 アルザ コーポレイション ゲル組成物および方法
EP1009390A4 (en) * 1997-07-02 2004-05-06 Euro Celtique Sa LONG-EFFECT ANESTHESIA INJECTED IN JOINT AND BODY SPACES
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US20030152637A1 (en) * 2001-01-25 2003-08-14 Mark Chasin Local anesthetic, and method of use
RU2355385C2 (ru) * 2002-11-06 2009-05-20 Алза Корпорейшн Композиции пролонгированного действия с контролируемым высвобождением
US20040137059A1 (en) * 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050245905A1 (en) * 2004-04-30 2005-11-03 Schmidt Steven P Local drug-delivery system
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8262605B2 (en) * 2004-12-09 2012-09-11 Ams Research Corporation Needleless delivery systems
US20100098735A1 (en) * 2006-10-05 2010-04-22 Rajesh Jain Injectable depot compositions and its process of preparation
CA2704111C (en) * 2007-05-14 2017-06-20 Sustained Nano Systems Llc Hypercompressed particles for controlled release of ophthalmic medications
EP2167039B1 (en) * 2007-05-18 2016-09-28 Durect Corporation Improved depot formulations
US20080317805A1 (en) * 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
US8828354B2 (en) * 2008-03-27 2014-09-09 Warsaw Orthopedic, Inc. Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin

Also Published As

Publication number Publication date
US8524267B2 (en) 2013-09-03
US20150065474A1 (en) 2015-03-05
EP2187866A2 (en) 2010-05-26
WO2009129155A3 (en) 2010-01-07
AU2009236419A1 (en) 2009-10-22
US9700567B2 (en) 2017-07-11
WO2009129155A2 (en) 2009-10-22
JP2011518164A (ja) 2011-06-23
EP2187866A4 (en) 2010-09-15
US20090263455A1 (en) 2009-10-22
US20130261095A1 (en) 2013-10-03
CN101917968A (zh) 2010-12-15
US8877226B2 (en) 2014-11-04

Similar Documents

Publication Publication Date Title
BRPI0904955A2 (pt) Depósito implantável de drogas para reduzir, prevenir ou tratar dor em um paciente em necessidade de tal tratamento e métodos para tratar dor aguda e para fazer um depósito de drogas implantável.
BRPI0905073A2 (pt) Depósito implantável de drogas para reduzir, prevenir ou tratar dor em um paciente em necessidade de tal tratamento e método para tratar dor aguda.
BRPI0904957A2 (pt) Depósito de droga implantável útil para reduzir, prevenir ou tratando dor pós-operatória em um paciente e métodos de tratar ou prevenir dor pós-operatória em um paciente e de produzir um depósito de droga implantável.
BRPI0904956A2 (pt) Depósito de medicamento implantável e método de tratamento ou prevenção de dor pós-operatória em um paciente
WO2007143231A3 (en) Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
WO2007100675A3 (en) Collagenase for treating cellulite
WO2010065671A3 (en) Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
BRPI0916007A2 (pt) "sistema de tratamento com pressão reduzida dinâmico para tratamento de um local tecidual em um paciente, método de produção de um sistema de tratamento com pressão reduzida dinâmico para tratar um local tecidual em paciente, método para tratamento de um local tecidual em um paciente, e, membro de aplicação de pressão reduzida"
BRPI0822162A8 (pt) método para tratamento de doenças das unhas ou leito ungueal e composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal.
WO2012002760A3 (ko) 세균유래 마이크로베시클을 이용한 암치료 및 암진단 방법
WO2010040112A3 (en) Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
BRPI0910198A2 (pt) composição para administração a partir de um sítio local de um agente baseado em nucleotídeos e método para tratar um sujeito sofrendo de uma doença requerendo tratamento local com um agente baseado em nucleotídeo.
BRPI0904962A2 (pt) Depósito de droga implantável útil para reduzir, prevenir ou tratar dor e/ou inflamação uma junta de faceta e/ou disco degenerativa em um paciente, e métodos de tratar e reduzir dor e/ou inflamação de uma junta de faceta e/ou disco degenerativa em um paciente
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2012062925A3 (en) Compounds and methods for treating pain
MX338512B (es) Dispositivo para tratamiento médico y/o cosmético.
MX2011007397A (es) Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
KZ24152B (en) Method of photosensitizer activation, treatment method with application of activated photosensitizer and photosensitizer application to prepare medicine
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
WO2007005716A3 (en) Methods of treatment and compositions for use thereof
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
BRPI0719276A2 (pt) Métodos para tratar, prevenir ou controlar uma doença associada com uma mutação sem sentido, para tratar, prevenir ou reduzir tosse, para aumentar expressão de distrofina em músculo de um paciente e para administrar um composto.
WO2010135056A3 (en) Phimosis treatment device and method
AR086051A1 (es) Metodo para tratar el cancer colorrectal, composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecano (folfiri), articulo manufacturado, kit
WO2011039736A3 (en) Device and method for drug delivery to a targeted skin layer

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.